Oncorus, Inc. (ONCR)
$1.18
Rating:
Recommendation:
-
| Symbol | ONCR |
|---|---|
| Price | $1.18 |
| Beta | 0.000 |
| Volume Avg. | 0.14M |
| Market Cap | 30.543M |
| Shares () | - |
| 52 Week Range | 1.03-17.79 |
| 1y Target Est | - |
| DCF Unlevered | ONCR DCF -> | |
|---|---|---|
| DCF Levered | ONCR LDCF -> | |
| ROE | -50.39% | Strong Sell |
| ROA | -39.58% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 54.53% | Buy |
| P/E | - | |
| P/B | 0.27 | Neutral |
Latest ONCR news
About
Download (Excel)Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.